共 50 条
Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
被引:1
|作者:
Yu, Jiahui
[1
]
Yan, Duan
[1
]
Wei, Song
[1
]
Yang, Linfeng
[1
]
Yi, Pengsheng
[1
]
机构:
[1] North Sichuan Med Coll, Affiliated Hosp, Dept Hepatobiliary Pancreas 2, 1 Maoyuan South Rd, Nanchong 637000, Sichuan, Peoples R China
关键词:
transcatheter arterial chemoembolization;
tyrosine kinase inhibitors;
camrelizumab;
hepatocellular carcinoma;
meta-analysis;
TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION;
TRANSARTERIAL CHEMOEMBOLIZATION;
DOUBLE-BLIND;
MULTICENTER;
APATINIB;
THERAPY;
ANTIBODIES;
LENVATINIB;
TRIALS;
D O I:
10.3892/ol.2024.14534
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Transcatheter arterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) and camrelizumab (collectively: T-T-C) is a novel treatment strategy for unresectable hepatocellular carcinoma (HCC). The present systematic review and meta-analysis aimed to evaluate the efficacy and safety of T-T-C compared with TACE combined with TKIs only (T-T) in the treatment of patients with unresectable HCC. A systematic literature search was conducted on T-T and T-T-C using PubMed, Embase and the Cochrane Library. Data regarding the clinical outcome, including overall survival (OS), progression-free survival (PFS), tumor response and adverse events (AEs), were independently extracted and analyzed by two researchers using standardized protocols. In total, 7 cohort studies, including 1,798 patients (T-T-C, 838; T-T, 960), were included in the meta-analysis. The results of the present study demonstrated that the T-T-C group had significantly prolonged OS [hazard ratio (HR), 0.38; 95% confidence interval (CI), 0.29-0.50; I2=61.5%; P=0.016)] and PFS (HR, 0.37; 95% CI, 0.30-0.46; I2=44.5%; P=0.109), and showed significantly higher objective response rates [risk ratio (RR), 0.82; 95% CI, 0.69-0.96; I2=25.1%; P=0.237)] and slightly higher disease control rates without a significant difference (RR, 0.96; 95% CI, 0.89-1.03; I2=0.0%; P=0.969). In addition, grade 3/4 AEs were more common in the T-T group, including hypertension (RR, 1.15; 95% CI, 0.85-1.56), vomiting or nausea (RR, 0.88; 95% CI, 0.44-1.76) and pain (RR, 0.74; 95% CI, 0.45-1.21); however, these results were not statistically significant. In conclusion, compared with T-T combination therapy, T-T-C demonstrated a notable advantage in terms of OS, PFS, ORR and DCR in patients with unresectable HCC. For manageable AEs, although the results were not statistically significant, the incidence of AEs in the T-T group was higher than that in the T-T-C group in terms of event probability.
引用
收藏
页数:12
相关论文